Neurochemical modulation of ingestive behavior in the ventral pallidum.
The nucleus accumbens and its related circuitry have been shown to play an important role in promoting the intake of hedonically desirable food. A previous report has demonstrated that the blockade of GABAA receptors in the ventral pallidum (VP), a target of GABAergic projection from the nucleus accumbens, greatly increases food, but not water, intake in satiated rats [Stratford et al. (1999)Brain Research, 825, 199-203]. The present study examined which neurotransmission in the VP is specifically involved in the intake of normally preferred taste stimuli. Microinjections of the GABAA antagonist bicuculline selectively increased the intake of saccharin solution but not that of water and quinine solution in water-deprived rats. In contrast, the facilitation of GABAA receptors by microinjections of muscimol in the VP generally suppressed the intake of saccharin, water and quinine. The same injections induced strong aversive taste reactivity responses to oral stimulation with not only quinine but also water and saccharin. The local administration of D-Ala2,N-Me-Phe4,Glyol5-enkephalin, a selective micro-opioid receptor agonist, into the VP had time-dependent effects, decreasing saccharine intake early and increasing intake late. Microinjections of SCH-23390, a dopamine D1 receptor antagonist, in the VP suppressed the intake of saccharin but not water or quinine. Microinjections of sulpiride, the dopamine D2 receptor antagonist, and 6-cyano-7-nitroquinoxaline-2,3-dione, the AMPA/kainate glutamate receptor antagonist, had no effect on fluid intake. These results reveal that GABA, opioid and D1 receptors in the VP are involved in the consumption of hedonically positive taste stimuli.
Department of Behavioral Physiology, Graduate School of Human Sciences, Osaka University, Suita, Osaka 565-0871 Japan. shimura@hus.osaka-u.ac.jp
Tsuyoshi
T
Shimura
Hiroyuki
H
Imaoka
Takashi
T
Yamamoto
D000818:Animals; D001070:Appetitive Behavior / Q000502:physiology*; D001923:Brain Chemistry / Q000502:physiology*; D018492:Dopamine Antagonists / Q000494:pharmacology; D065127:Dopamine D2 Receptor Antagonists; D004327:Drinking Behavior / Q000187:drug effects; D004347:Drug Interactions; D018755:GABA Agonists / Q000494:pharmacology; D018756:GABA Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D058785:GABA-A Receptor Agonists; D058787:GABA-A Receptor Antagonists; D005917:Globus Pallidus / Q000502:physiology*; D008297:Male; D008845:Microinjections; D009043:Motor Activity / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D018091:Receptors, AMPA / Q000037:antagonists & inhibitors; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors; D017450:Receptors, Opioid, mu / Q000819:agonists; D009435:Synaptic Transmission / Q000502:physiology; D013649:Taste / Q000502:physiology
D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D018755:GABA Agonists; D018756:GABA Antagonists; D058785:GABA-A Receptor Agonists; D058787:GABA-A Receptor Antagonists; D018091:Receptors, AMPA; D017447:Receptors, Dopamine D1; D017450:Receptors, Opioid, mu